A case study on the ecosystem for local production of pharmaceuticals, vaccines and biologicals: the Nigeria context

Simple item page
dc.coverageGeneva
dc.creatorWorld Health Organization
dc.date2024-05-06T04:52:14Z
dc.date2024-05-06T04:52:14Z
dc.date2024-05-06
dc.date.accessioned2026-08-03T13:16:16Z
dc.descriptionxv, 67 p.
dc.descriptionNigeria remains heavily dependent on imported vaccines and a large proportion of its pharmaceutical products despite having a sizeable and growing pharmaceutical manufacturing industry. This case study examines the ecosystem for local production of pharmaceuticals, vaccines and biologicals in Nigeria, with particular attention to preparedness for vaccine manufacturing and participation in the WHO mRNA technology transfer initiative. Based on a review of literature, policies and strategic documents, questionnaires administered to pharmaceutical manufacturers, and consultations with key stakeholders, the report assesses the policy environment, financing mechanisms, regulatory capacity, research and development infrastructure, intellectual property framework, technology transfer opportunities and market conditions relevant to local production. The analysis highlights existing strengths, including a functional pharmaceutical manufacturing sector, supportive national policies and an increasingly mature regulatory system, while identifying persistent challenges such as dependence on imported inputs, inadequate financing, infrastructure constraints, limited policy implementation and insufficient support for research and development. The publication also reviews national strategies and partner-supported initiatives aimed at strengthening local production and re-establishing vaccine manufacturing capacity. It concludes with recommendations to enhance coordination, investment, regulatory capacity and innovation in support of sustainable local production, improved access to quality-assured health products and greater health security in Nigeria.
dc.formatapplication/pdf
dc.identifier9789240092761 (electronic version)
dc.identifier9789240092778 (print version)
dc.identifierhttps://iris.who.int/handle/10665/376688
dc.identifier.urihttps://repo.dare.co.zw/handle/123456789/259011
dc.languageEnglish
dc.languageen
dc.publisherWorld Health Organization
dc.rightsCC BY-NC-SA 3.0 IGO
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/3.0/igo
dc.rightsWorld Health Organization
dc.subjectEcosystem
dc.subjectDrug Industry
dc.subjectManufacturing and Industrial Facilities
dc.subjectPharmaceutical Preparations
dc.subjectDrugs, Essential
dc.subjectVaccines
dc.subjectBiological Products
dc.subjectVaccine-Preventable Diseases
dc.subjectCommunicable Diseases
dc.subjectTechnology Transfer
dc.subjectGovernment
dc.subjectOrganizational Case Studies
dc.subjectNigeria
dc.subjectsupply and distribution
dc.subjectstatistics and numerical data
dc.titleA case study on the ecosystem for local production of pharmaceuticals, vaccines and biologicals: the Nigeria context
dc.typePublications

Files

Collections

WHO IRIS